



Time for a Paradigm Shift in Non-muscle Invasive Bladder Cancer

Guest Editor:

**Prof. Dr. Jørgen Bjerggaard
Jensen**

Department of Clinical Medicine,
Aarhus University, 8200 Aarhus,
Denmark

Deadline for manuscript
submissions:

closed (15 May 2022)

Message from the Guest Editor

Dear Colleagues,

Non-Muscle Invasive Bladder Cancer (NMIBC) is a vary heterogeneous disease with a variety of treatment modalities and different follow-up regimens. Most cases of NMIBC are treated with TURBT and potential adjuvant instillation therapy, whereas the minority is treated by radical cystectomy. However, despite this variety of treatment modalities that have optimized slightly over the last few decades, a recurrence rate of more than 50% of all patients highlights the urgent need for a more optimal treatment up front. Moreover, piecemeal TURBT in NMIBC that violates normal oncological principles and life-long follow-up regimens based on traditional pathology risk stratification in a disease where biomarkers have been studied for decades calls for a change.

In this Special Issue of *Cancers*, we will highlight studies where traditional approaches to NMIBC is questioned and challenged and new treatment regimens are investigated.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)